Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.
Wan EYF, Wang B, Mathur S, Chan CIY, Yan VKC, Lai FTT, Chui CSL, Li X, Wong CKH, Li PH, Lau CS, Wong ICK, Chan EWY.
Wan EYF, et al. Among authors: chan ciy.
J Infect. 2023 Jun;86(6):622-625. doi: 10.1016/j.jinf.2023.02.029. Epub 2023 Feb 22.
J Infect. 2023.
PMID: 36822409
Free PMC article.
No abstract available.